Mustang Bio Inc (MBIO)

Mar 5, 2025, 4:15 PM EST - 4 weeks ago

Mustang Bio Regains Compliance with Nasdaq Capital Market Requirement

FBIO

Feb 27, 2025, 4:05 PM EST - 5 weeks ago

Mustang Bio Announces Sale of Fixed Assets and Exit of Facility

Feb 11, 2025, 4:10 PM EST - 7 weeks ago

Mustang Bio Regains Compliance with Nasdaq Minimum Bid Price Requirement

Feb 10, 2025, 8:00 AM EST - 7 weeks ago

Mustang Bio Announces Closing of $8 Million Public Offering

Feb 6, 2025, 7:00 AM EST - 2 months ago

Mustang Bio Announces Pricing of $8 Million Public Offering

Jan 14, 2025, 8:00 AM EST - 2 months ago

Mustang Bio Announces Reverse Stock Split

Nov 12, 2024, 8:30 AM EST - 5 months ago

Mustang Bio Receives Positive Listing Determination from Nasdaq

Nov 7, 2024, 8:30 AM EST - 5 months ago

Mustang Bio Granted Orphan Drug Designation by U.S. FDA for MB-108 (HSV-1 oncolytic virus) to Treat Malignant Glioma

Oct 24, 2024, 2:10 PM EDT - 5 months ago

Mustang Bio Announces Exercise of Warrants for $4 Million Gross Proceeds

Jun 28, 2024, 8:00 AM EDT - 9 months ago

Diamond Equity Research Releases Update Note on Enveric Biosciences Inc. (NASDAQ: ENVB)

ENVB

Jun 21, 2024, 4:01 PM EDT - 10 months ago

Mustang Bio Announces Closing of $2.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Jun 20, 2024, 8:00 AM EDT - 10 months ago

Mustang Bio Announces $2.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Jun 18, 2024, 2:52 AM EDT - 10 months ago

Why are Mustang Bio shares (MBIO) up almost 500%?

Jun 17, 2024, 9:21 AM EDT - 10 months ago

Why Is Penny Stock Mustang Bio Trading Over 190% On Monday?

Jun 17, 2024, 8:30 AM EDT - 10 months ago

Mustang Bio Announces Favorable Efficacy and Safety Data from Complete Waldenstrom Macroglobulinemia Cohort of Phase 1/2 Clinical Trial of MB-106, CD20-Targeted Autologous CAR-T Therapy

May 2, 2024, 4:01 PM EDT - 1 year ago

Mustang Bio Announces Closing of $4 Million Public Offering

Apr 29, 2024, 8:00 PM EDT - 1 year ago

Mustang Bio Announces Pricing of $4 Million Public Offering

Mar 28, 2024, 9:00 AM EDT - 1 year ago

Mustang Bio Announces Vision for CAR T-Cell Therapy Platform Expansion into Autoimmune Diseases

Mar 11, 2024, 4:05 PM EDT - 1 year ago

Mustang Bio Reports Full-Year 2023 Financial Results and Recent Corporate Highlights

Mar 7, 2024, 7:30 AM EST - 1 year ago

Mustang Bio Announces Publication in Nature Medicine of Data from Phase 1 Trial Evaluating MB-101 IL13Rα2-targeted CAR T-Cells in High-Grade Glioma

Jan 11, 2024, 8:30 AM EST - 1 year ago

Mustang Bio to Participate in the B. Riley Securities 4th Annual Oncology Conference

Dec 11, 2023, 8:30 AM EST - 1 year ago

Mustang Bio Presents Updated Phase 1/2 Multicenter Clinical Data for MB-106 at the 2023 American Society of Hematology (ASH) Annual Meeting

Nov 14, 2023, 4:05 PM EST - 1 year ago

Mustang Bio Reports Third Quarter 2023 Financial Results and Recent Corporate Highlights

Nov 2, 2023, 9:28 AM EDT - 1 year ago

Mustang Bio Announces MB-106 CD20-Targeted CAR-T Data Selected for Presentation at 65th American Society of Hematology (ASH) Annual Meeting

Oct 30, 2023, 2:15 PM EDT - 1 year ago

Mustang Bio Announces Closing of $4.4 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Oct 26, 2023, 12:30 PM EDT - 1 year ago

Mustang Bio Announces $4.4 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Oct 26, 2023, 9:00 AM EDT - 1 year ago

Mustang Bio Announces FDA Acceptance of IND Application for MB-109, a Novel Combination of MB-101 (IL13Rα2‐targeted CAR-T cell therapy) and MB-108 (HSV-1 oncolytic virus), for the Treatment of Recurrent Glioblastoma and High-Grade Astrocytoma

Sep 7, 2023, 8:15 AM EDT - 1 year ago

Mustang Bio to Participate in Upcoming September 2023 Investor Conferences

Aug 16, 2023, 8:00 AM EDT - 1 year ago

Mustang Bio Announces First Data from Ongoing Multicenter Phase 1/2 Clinical Trial Evaluating MB-106 CAR-T Cell Therapy

Aug 14, 2023, 4:05 PM EDT - 1 year ago

Mustang Bio Reports Second Quarter 2023 Financial Results and Recent Corporate Highlights

Aug 3, 2023, 8:00 AM EDT - 1 year ago

Mustang Bio to Participate in Two August 2023 Investor Conferences

Jul 31, 2023, 8:30 AM EDT - 1 year ago

Mustang Bio Announces Amendment and Closing of Strategic Manufacturing Partnership Transaction with uBriGene (Boston) Biosciences

Jul 6, 2023, 8:00 AM EDT - 1 year ago

Mustang Bio Announces Participation in Upcoming Scientific Meetings

Jun 15, 2023, 4:01 PM EDT - 1 year ago

Mustang Bio Announces Final Results from Follicular Lymphoma Cohort of Single-Institution Phase 1/2 Clinical Trial of MB-106, CD20-Targeted Autologous CAR T Therapy

Jun 12, 2023, 8:00 AM EDT - 1 year ago

Mustang Bio Announces Updated Results from Waldenstrom Macroglobulinemia Cohort of Ongoing Phase 1/2 Clinical Trial of MB-106, CD20-Targeted Autologous CAR T Therapy

May 18, 2023, 8:03 AM EDT - 2 years ago

Mustang Bio Announces Strategic Manufacturing Partnership and Portfolio Updates

May 12, 2023, 4:05 PM EDT - 2 years ago

Mustang Bio Reports First Quarter 2023 Financial Results and Recent Corporate Highlights

May 11, 2023, 4:03 PM EDT - 2 years ago

Mustang Bio Announces Upcoming Presentations of Clinical Data from Phase 1/2 Trial of MB-106, a CD20-Targeted Autologous CAR T Cell Therapy

Mar 29, 2023, 4:15 PM EDT - 2 years ago

Mustang Bio Reports Full-Year 2022 Financial Results and Recent Corporate Highlights

Mar 28, 2023, 8:30 AM EDT - 2 years ago

Mustang Bio to Participate in Cantor's The Future of Oncology Virtual Symposium

Jan 17, 2023, 8:15 AM EST - 2 years ago

Mustang Bio to Participate in the B. Riley Securities' 3rd Annual Oncology Conference

Dec 19, 2022, 8:30 AM EST - 2 years ago

Mustang Bio Provides CAR T Cell Therapy Portfolio Updates and 2023 Anticipated Milestones

Nov 14, 2022, 4:05 PM EST - 2 years ago

Mustang Bio Reports Third Quarter 2022 Financial Results and Recent Corporate Highlights

Oct 27, 2022, 8:00 AM EDT - 2 years ago

Mustang Bio Announces Phase 1/2 Clinical Trial Data of MB-106, a First-in-Class CD20-targeted, Autologous CAR T Cell Therapy, to be Presented at 11th International Workshop for Waldenstrom's Macroglobulinemia

Oct 6, 2022, 8:30 AM EDT - 2 years ago

Mustang Bio Announces First Patient Treated in Its Multicenter Phase 1/2 Clinical Trial of MB-106, a First-in-Class CD20-targeted, Autologous CAR T Cell Therapy to Treat B-cell Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia

Sep 23, 2022, 4:55 PM EDT - 2 years ago

Mustang Bio: This Horse May Gallop Still

Sep 8, 2022, 8:00 AM EDT - 2 years ago

Mustang Bio to Participate in Upcoming September 2022 Investor Conferences

Aug 11, 2022, 4:05 PM EDT - 2 years ago

Mustang Bio Reports Second Quarter 2022 Financial Results and Recent Corporate Highlights

Jul 27, 2022, 8:00 AM EDT - 2 years ago

Mustang Bio Announces First Patient Successfully Treated by Ex Vivo Lentiviral Gene Therapy to Treat RAG1 Severe Combined Immunodeficiency

Jun 22, 2022, 8:00 AM EDT - 3 years ago

Mustang Bio Announces Orphan Drug Designation Granted to MB-106, a CD20-targeted, Autologous CAR T Cell Therapy for the Treatment of Waldenstrom Macroglobulinemia